低危患者经导管主动脉瓣植入术的前景探讨
本文综述经导管主动脉瓣植入术(TAVI)在低至中危重度主动脉瓣狭窄患者中的现有证据,指出指南已在高危患者中将TAVI与外科主动脉瓣置换(SAVR)推荐等同,中危患者中TAVI可作为SAVR替代方案,低危患者角色尚待正在进行的随机试验明确。
要点
- 在高危患者中,指南推荐TAVI与SAVR等效。
- 中危患者中,经合理筛选后TAVI可作为SAVR的替代方案。
- 低危患者中TAVI的角色是正在进行的随机试验的目标。
核心结论
- TAVI在中危患者中已成为SAVR的替代方案,低危患者中的角色尚待正在进行的随机试验明确。
研究设计与样本
- 综述,总结低至中危患者中TAVI的现有知识并讨论其潜在优势与陷阱。
主要发现
- 操作者经验增加、新一代经导管心脏瓣膜技术进步及近期随机对照试验的优异结果推动了TAVI适应证向中危患者扩展。
关键数值与推荐
- 当前指南指出,在高危患者中TAVI与SAVR的推荐等级等同。
- 中危患者中,经适当患者选择,TAVI可作为SAVR的替代方案。
临床怎么用
- 高危患者可考虑TAVI与SAVR等效;中危患者经合理筛选后可选TAVI;低危患者应等待随机试验结果。
局限性
- 低危患者中TAVI的证据尚待正在进行的随机试验结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the last decade, transcatheter aortic valve implantation (TAVI), a disruptive technology, has revolutionized the therapy of symptomatic severe aortic stenosis, and current guidelines state that the recommendations for TAVI and surgical aortic valve replacement (SAVR) are equivalent in patients at high-risk. Increased operator experience, technical advances in the new generation of transcatheter heart valves (THV) and excellent TAVI results in recently published randomized controlled trials have led to the expansion of TAVI indication as an alternative to SAVR in intermediate-risk subjects, given appropriate patient selection. The time is opportune to examine the role of TAVI in low-risk patients, currently the objective of on-going randomized trials. This review aims to summarize the available knowledge on TAVI in low- to intermediate-risk patients and to discuss the potential advantages and pitfalls TAVI will face in this clinical setting.
引用
- Tarantini G, Nai Fovino L, Gersh BJ, et al. Transcatheter aortic valve implantation in lower-risk patients: what is the perspective? Eur Heart J. 2018. PMID: 29020347. doi:10.1093/eurheartj/ehx489
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。